āĻšā§āĻŽAXGN âĸ NASDAQ
add
AxoGen, Inc Common Stock
ā§§ā§Ž.ā§§ā§¨$
ā§§ā§Š āĻāĻžāĻ¨ā§, ā§§ā§§:ā§Ģā§Ž:ā§¨ā§Ž AM GMT -ā§Ģ · USD · NASDAQ · āĻĄāĻŋāĻ¸āĻā§āĻ˛ā§āĻŽāĻžāĻ°
āĻ¸ā§āĻāĻāĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ āĻ¯ā§āĻā§āĻ¤āĻ°āĻžāĻˇā§āĻā§āĻ°-āĻ āĻ¤āĻžāĻ˛āĻŋāĻāĻžāĻā§āĻā§āĻ¤ āĻ¸āĻŋāĻāĻŋāĻāĻ°āĻŋāĻāĻŋāĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ āĻ¯ā§āĻā§āĻ¤āĻ°āĻžāĻˇā§āĻā§āĻ°-āĻ āĻšā§āĻĄāĻā§ā§āĻžāĻ°ā§āĻāĻžāĻ°
āĻāĻžāĻ˛ āĻļā§āĻˇ āĻ¯ā§ āĻĻāĻžāĻŽā§ āĻāĻŋāĻ˛
ā§§ā§Ž.ā§Ļā§Ģ$
āĻ¸āĻžāĻ°āĻž āĻĻāĻŋāĻ¨ā§āĻ° āĻā§āĻ°ā§āĻĄāĻŋāĻā§ā§ āĻ¸ā§āĻāĻā§āĻ° āĻĻāĻžāĻŽā§āĻ° āĻāĻ āĻž āĻ¨āĻžāĻŽāĻžāĻ° āĻ°ā§āĻā§āĻ
ā§§ā§.ā§§ā§$ - ā§§ā§Ž.ā§Ēā§¯$
āĻ¸āĻžāĻ°āĻž āĻŦāĻāĻ°ā§āĻ° āĻ°ā§āĻā§āĻ
ā§Ģ.ā§Ģā§Ŧ$ - ā§§ā§Ž.ā§Ēā§¯$
āĻŽāĻžāĻ°ā§āĻā§āĻ āĻā§āĻ¯āĻžāĻĒ
ā§Žā§Ļ.ā§Ļā§Ģ āĻā§ USD
āĻāĻĄāĻŧ āĻāĻ˛āĻŋāĻāĻŽ
ā§Š.ā§¯ā§¨Â āĻ˛āĻž
P/E āĻ
āĻ¨ā§āĻĒāĻžāĻ¤
-
āĻ˛āĻā§āĻ¯āĻžāĻāĻļ āĻĒā§āĻ°āĻĻāĻžāĻ¨
-
āĻĒā§āĻ°āĻžāĻāĻŽāĻžāĻ°āĻŋ āĻāĻā§āĻ¸āĻā§āĻā§āĻ
NASDAQ
āĻāĻŦāĻ°ā§ āĻ°ā§ā§āĻā§
āĻĢāĻžāĻāĻ¨āĻžāĻ¨ā§āĻ¸āĻŋā§āĻžāĻ˛ āĻĒāĻžāĻ°āĻĢāĻ°ā§āĻŽā§āĻ¯āĻžāĻ¨ā§āĻ¸
āĻā§ā§āĻ° āĻ¸ā§āĻā§āĻāĻŽā§āĻ¨ā§āĻ
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ
| (USD) | āĻ¸ā§āĻĒ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§Ē.ā§Žā§Ŧ āĻā§ | ā§§ā§.ā§Žā§Ŧ% |
āĻŦā§āĻ¯āĻŦāĻ¸āĻž āĻāĻžāĻ˛āĻžāĻ¨ā§āĻ° āĻāĻ°āĻ | ā§Š.ā§Ŧā§ŽÂ āĻā§ | ā§¨.ā§Žā§% |
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§§ā§Ž.ā§Ģā§ŽÂ āĻ˛āĻž | ā§Ģā§Ē.ā§Ģā§Ŧ% |
āĻ¨ā§āĻ āĻĒā§āĻ°āĻĢāĻŋāĻ āĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ | -ā§Š.ā§Žā§¨ | ā§Ŧā§§.ā§Ēā§Ģ% |
āĻļā§ā§āĻžāĻ° āĻĒā§āĻ°āĻ¤āĻŋ āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§Ļ.ā§Ļā§ | ā§Ŧā§Ļā§Ļ.ā§Ļā§Ļ% |
EBITDA | ā§§ā§Ē.ā§Ļā§¨Â āĻ˛āĻž | ā§§ā§Ģā§Ļ.ā§Ļā§Ģ% |
āĻĒā§āĻ°āĻ¯ā§āĻā§āĻ¯ āĻā§āĻ¯āĻžāĻā§āĻ¸ā§āĻ° āĻšāĻžāĻ° | â | â |
āĻŦā§āĻ¯āĻžāĻ˛ā§āĻ¨ā§āĻ¸ āĻļāĻŋāĻ
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
| (USD) | āĻ¸ā§āĻĒ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻā§āĻ¯āĻžāĻļ āĻ āĻāĻŽ āĻ¸āĻŽā§ā§āĻ° āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ | ā§¨.ā§Ēā§Ģ āĻā§ | -ā§¨ā§Ē.ā§ā§Š% |
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ | ā§§ā§¯.ā§¨ā§Ļ āĻā§ | -ā§§.ā§Šā§Ŧ% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§¯.ā§¨ā§Ŧ āĻā§ | -ā§Ē.ā§Šā§Ž% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§¯.ā§¯ā§Ē āĻā§ | â |
āĻāĻāĻāĻ¸ā§āĻā§āĻ¯āĻžāĻ¨ā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāĻ° | ā§Ē.ā§Ēā§ĻÂ āĻā§ | â |
āĻĒā§āĻ°āĻžāĻāĻ¸ āĻā§ āĻŦā§āĻ āĻ°ā§āĻļāĻŋāĻ | ā§.ā§¯ā§¯ | â |
āĻ¸āĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | -ā§Ļ.ā§Ēā§§% | â |
āĻŽā§āĻ˛āĻ§āĻ¨ āĻĨā§āĻā§ āĻā§ | -ā§Ļ.ā§Ēā§% | â |
āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨
| (USD) | āĻ¸ā§āĻĒ ā§¨ā§Ļā§¨ā§Ēinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
|---|---|---|
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§§ā§Ž.ā§Ģā§ŽÂ āĻ˛āĻž | ā§Ģā§Ē.ā§Ģā§Ŧ% |
āĻ
āĻĒāĻžāĻ°ā§āĻļāĻ¨ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āĻ¯āĻžāĻļ | ā§Šā§¯.ā§Ļā§§Â āĻ˛āĻž | ā§§ā§Šā§¯.ā§¯ā§§% |
āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | -ā§Ģā§Ļ.ā§Ļā§Ļ āĻ˛āĻž | -ā§§ā§Žā§Š.ā§Ēā§¨% |
āĻĢāĻžāĻāĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¸āĻŋāĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | ā§Ģ.ā§ā§¨Â āĻ˛āĻž | ā§§ā§§,ā§Šā§Ēā§Ļ.ā§Ļā§Ļ% |
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ | -ā§Ģ.ā§¨ā§Â āĻ˛āĻž | -ā§§ā§Ļā§Ŧ.ā§¯ā§§% |
āĻĢā§āĻ°āĻŋ āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§ | ā§Šā§Ģ.ā§¯ā§Ģ āĻ˛āĻž | ā§Ēā§¨ā§Ē.ā§Šā§Ģ% |
āĻ¸āĻŽā§āĻĒāĻ°ā§āĻā§
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāĻ¤ āĻšā§ā§āĻā§
ā§¨ā§Ļā§Ļā§¨
āĻ¸āĻĻāĻ° āĻĻāĻĒā§āĻ¤āĻ°
āĻā§ā§āĻŦāĻ¸āĻžāĻāĻ
āĻāĻ°ā§āĻŽāĻāĻžāĻ°ā§
ā§Ēā§¨ā§
